One potential solution to the Trump administration's more assertive posture on pharmaceutical pricing in benchmark countries like Australia is to raise the published list PBS price paid to manufacturers. Yet it could have unintended consequences.
A simple increase in published list prices could have unintended consequences
February 10, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Setting the standard for safe and accountable virtual healthcare in Australia
March 4, 2026 - - Latest News -
A system built for a past is struggling to meet the challenge of today, let alone the future
March 4, 2026 - - Latest News -
Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates
March 4, 2026 - - Australian Biotech -
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 - - Australian Biotech -
Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment
March 4, 2026 - -
PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
March 4, 2026 - - Australian Biotech -
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 - - Australian Biotech

